Back to news

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

PR Newswire•17/11/2026•19:02 ET
0

Key Highlights

  • ➤Adrenyx expects Nasdaq listing in the first half of 2027.
  • ➤Adrenyx secured an initial US$5 million convertible note arrangement.
  • ➤Convertible notes may reach US$10 million aggregate principal amount.
  • ➤Private placement could provide up to US$50 million, including notes funding.
  • ➤CRHX-101 IND filing and clinical program initiation are near-term priorities.

Expert Statements

Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed

“We are pleased to see the continued advancement of CRHX-101 through a dedicated corporate structure. The establishment of Adrenyx reflects a focused approach to advancing CRHX-101 and supporting its next stage of development. We look forward to the continued progress of CRHX-101 in addressing the significant unmet medical needs of people living with CAH.”

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company PR Newswire

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in